• Login
    View Item 
    •   Athenaeum Home
    • BioMed Central Open Access Articles
    • Open Access Articles by UGA Faculty
    • View Item
    •   Athenaeum Home
    • BioMed Central Open Access Articles
    • Open Access Articles by UGA Faculty
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Interventions for post-infectious irritable bowel syndrome: a systematic review of treatment efficacy

    Thumbnail
    View/Open
    40794_2015_Article_2.pdf (637.7Kb)
    Date
    2015-07-31
    Author
    Torbicki, Emma
    Oh, Justin
    Mishra, Sharmistha
    Page, Andrea V
    Boggild, Andrea K
    Metadata
    Show full item record
    Abstract
    Abstract Background Post-infectious irritable bowel syndrome (PI-IBS) due to traveler’s diarrhea is the second most common illness seen in post-travel clinics, yet its optimal management remains unknown. We performed a systematic review to evaluate treatment efficacy in PI-IBS. Methods We searched Medline, EMBASE, LILACS, CINAHL, CAB abstracts, and the Cochrane Library to February 3, 2014 for intervention studies of the pharmacologic and non-pharmacologic management of PI-IBS and examined the evidence according to a modified Grading of Recommendations Assessment, Development, and Evaluation (GRADE) scale. Results Of 336 records, 9 studies were included. Eight studies of pharmacologic interventions examined 5 agents (mesalazine or mesalamine, ondansetron, prednisolone, cholestyramine, and metronidazole). One study examined the non-pharmacologic intervention of different infant nutritional formulas following acute gastroenteritis. The quality of the evidence to date was low, with small sample size (fewer than 50 participants) and short duration of follow-up. Overall, the efficacy of pharmacological treatment ranged from no benefit (ondansetron and prednisolone) to moderately beneficial (cholestyramine and metronidazole). The evidence for mesalazine was equivocal: one study showed benefit, two others showed none. Conclusions Heterogeneity in outcome measures and low strength of evidence preclude recommendations on the optimal management of PI-IBS by a specific agent. More comparative intervention research into PI-IBS treatment is needed for consistent best practice in PI-IBS management. Clinicians may elect to pursue therapeutic trials of mesalazine, cholestyramine, or metronidazole in individual patients, but should be aware that data supporting the efficacy of these agents is limited.
    URI
    http://dx.doi.org/10.1186/s40794-015-0002-9
    http://hdl.handle.net/10724/32087
    Collections
    • Open Access Articles by UGA Faculty

    About Athenaeum | Contact Us | Send Feedback
     

     

    Browse

    All of AthenaeumCommunities & CollectionsBy Issue DateAuthorsTitlesSubjectsThis CollectionBy Issue DateAuthorsTitlesSubjects

    My Account

    LoginRegister

    About Athenaeum | Contact Us | Send Feedback